(95) suggested that ibrutinib enhances antitumor immune responses by inhibiting STAT3-induced selective and persistent downregulation of PD-L1 on CLL cells and PD-1 in CD4+ and CD8+ T cells. Here, CD4 is linked to B-cell chronic lymphocytic leukemia.